Detalles de la búsqueda
1.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Int J Cancer
; 154(12): 2142-2150, 2024 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38447003
2.
Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4073-4083, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38459418
3.
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Int J Cancer
; 153(10): 1726-1733, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37455496
4.
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
Int J Cancer
; 153(1): 153-163, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36883420
5.
Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
BMC Cancer
; 23(1): 561, 2023 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37337155
6.
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry.
Int J Cancer
; 148(6): 1478-1488, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33038277
7.
Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma - the phase III "PREVENT"- (FLOT9) trial of the AIO /CAOGI /ACO.
BMC Cancer
; 21(1): 1158, 2021 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34715810
8.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
Int J Cancer
; 147(9): 2493-2502, 2020 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32339253
9.
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Lancet
; 393(10184): 1948-1957, 2019 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30982686
10.
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
BMC Cancer
; 20(1): 886, 2020 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32933498
11.
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) - a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)- the AIO/ CALGP/ ACO- GAIN-trial.
BMC Cancer
; 20(1): 122, 2020 Feb 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32059704
12.
ASO Visual Abstract: Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer-The Randomized Multicenter Phase II NEPAFOX Trial.
Ann Surg Oncol
; 31(6): 4121-4122, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575722
13.
The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.
BMC Cancer
; 17(1): 893, 2017 12 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-29282088
14.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Lancet Oncol
; 17(12): 1697-1708, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27776843
15.
A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
Cancer
; 122(9): 1425-33, 2016 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26949913
16.
Perioperative chemotherapy for gastric cancer in FLOT4 - Authors' reply.
Lancet
; 395(10218): e4, 2020 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31929022
17.
VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
BMC Cancer
; 14: 476, 2014 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24981311
18.
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Gastric Cancer
; 17(1): 181-7, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23455717
19.
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
J Clin Oncol
; 42(4): 410-420, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37963317
20.
Dissecting the genetic heterogeneity of gastric cancer.
EBioMedicine
; 92: 104616, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209533